Executive order to speed access to psychedelic treatments likely to have limited legal impact despite high-profile push

Executive order to speed access to psychedelic treatments likely to have limited legal impact despite high-profile push

It's a big shift toward supporting psychedelic-based medicines for treatment-resistant depression, PTSD and substance use disorders, the FDA said.

The FDA announced regulatory actions Friday to support development of serotonin-2A agonists and related products, including psychedelic drugs.